Pembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC

The management of advanced non-small cell lung cancer (NSCLC) has evolved significantly with the introduction of immune checkpoint inhibitors. While these therapies have demonstrated superior efficacy in many settings, their distinct adverse event profiles, particularly immune-related adverse events (irAEs), necessitate careful consideration. Pulmonary irAEs, such as pneumonitis, are a known complication of PD-1/PD-L1 inhibitors, yet a comprehensive comparison of overall pulmonary adverse event burden between pembrolizumab and chemotherapy has been a focus of recent analysis.

Background and Clinical Rationale

NSCLC accounts for approximately 85% of all lung cancers, and a significant proportion of patients present with advanced or metastatic disease. Historically, platinum-based chemotherapy regimens formed the backbone of first-line treatment for these patients. However, chemotherapy is associated with a range of systemic toxicities, including myelosuppression, gastrointestinal disturbances, and fatigue, which can significantly impact patient quality of life and treatment adherence. Pulmonary complications, such as chemotherapy-induced pneumonitis, opportunistic infections due to immunosuppression, and exacerbation of underlying lung conditions, also represent a substantial burden. The advent of immune checkpoint inhibitors, particularly pembrolizumab, a humanized monoclonal antibody that blocks the PD-1 receptor, has revolutionized NSCLC treatment, especially in patients with high PD-L1 expression or in combination with chemotherapy regardless of PD-L1 status. Understanding the full spectrum of adverse events, beyond just immune-related toxicities, is crucial for informed clinical decision-making and patient management.

Comparative Pulmonary Safety Profile

A pooled analysis of several pivotal trials, including KEYNOTE-024, KEYNOTE-042, and KEYNOTE-189, evaluated the incidence of pulmonary adverse events in patients with advanced NSCLC receiving first-line pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy, compared to chemotherapy alone. The analysis specifically focused on events classified as pulmonary, respiratory, thoracic, and mediastinal disorders.

The methodology involved a systematic review of adverse event data from these large, randomized, controlled trials. KEYNOTE-024 enrolled patients with previously untreated, advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%. KEYNOTE-042 included patients with advanced NSCLC and PD-L1 TPS ≥1%. KEYNOTE-189 evaluated pembrolizumab plus platinum-pemetrexed chemotherapy in patients with metastatic non-squamous NSCLC, regardless of PD-L1 expression. The patient populations across these trials were generally representative of advanced NSCLC patients, encompassing various histological subtypes (primarily non-squamous and squamous) and performance statuses. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. The pooled analysis allowed for a robust comparison of safety profiles across a large cohort of patients, providing a comprehensive overview of pulmonary toxicity.

The data revealed that pembrolizumab monotherapy was associated with a lower incidence of all-grade pulmonary adverse events compared to platinum-based chemotherapy. In patients receiving pembrolizumab monotherapy, the incidence of all-grade pulmonary AEs was 13.3%. In contrast, patients treated with platinum-based chemotherapy experienced an incidence of 23.9% for all-grade pulmonary AEs. This difference was statistically significant (p < 0.001).

When considering Grade 3-5 pulmonary adverse events, the rates were also lower with pembrolizumab monotherapy, at 2.8%, compared to 5.2% for chemotherapy (p < 0.01). The most common pulmonary adverse events reported in the chemotherapy arm included dyspnoea, cough, and pneumonia. While pneumonitis is a known irAE associated with pembrolizumab, its overall contribution to the total pulmonary AE burden was lower than the collective pulmonary events observed with chemotherapy.

The combination of pembrolizumab with chemotherapy also showed a numerically lower, though not statistically significant, rate of all-grade pulmonary AEs (20.1%) compared to chemotherapy alone (23.9%). For Grade 3-5 events, the combination arm reported 4.1%, compared to 5.2% for chemotherapy alone.

These findings suggest that while immune-related pneumonitis is a specific concern with pembrolizumab, the broader spectrum of pulmonary adverse events, including those related to myelosuppression and infection commonly seen with chemotherapy, contributes to a higher overall pulmonary toxicity burden in the chemotherapy arm. The mechanism for the observed reduction in pulmonary AEs with pembrolizumab monotherapy versus chemotherapy is multifactorial, likely involving differences in direct lung toxicity, immunosuppression leading to infection, and exacerbation of pre-existing lung conditions.

Limitations and Future Directions

Despite the robust nature of this pooled analysis, certain limitations warrant consideration. The analysis relied on adverse event reporting from individual trials, which may have inherent variability in assessment and documentation. While the NCI CTCAE provides standardized grading, subjective interpretation can still occur. Furthermore, the specific etiologies of all pulmonary adverse events were not always definitively established, making it challenging to precisely differentiate between immune-related, infection-related, or chemotherapy-induced events in all cases. The pooled analysis also combined data from trials with slightly different patient selection criteria and chemotherapy regimens, which could introduce heterogeneity. Future research could involve prospective studies specifically designed to compare pulmonary toxicity profiles with detailed adjudication of event etiologies. Real-world data analyses could also provide further insights into the long-term pulmonary safety of these treatments in broader patient populations, including those with significant comorbidities often excluded from clinical trials.